Skip to content

Eton Pharmaceuticals, Inc. ETON Hemangeol — Other Commitment

Similar metrics at other companies

IBT
IBTAOther Commitment
$37.09M+28.4%
Inter Parfums logo
IPAROther Commitment
$1.31B+72.5%
Rayonier logo
RYNOther Commitment
$12.91M
Rumble, Inc. logo
RUMOther Commitment
$50M
BGC Group, Inc. logo
BGCOther Commitment
$0
Chicago Atlantic Real Estate Finance logo
REFIOther Commitment
$0

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$953.8M+162%
Enterprise value$965.4M+156%
P/S11×+3.4×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherCommitment.

The official record: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s hemangeol — other commitment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s hemangeol — other commitment?
Eton Pharmaceuticals, Inc. (ETON) reported hemangeol — other commitment of $700K in Q1 2026.
What does hemangeol — other commitment mean?
This metric captures miscellaneous contractual obligations or future financial commitments related to the commercialization of a specific product that do not fall under standard royalty or acquisition categories. It may include milestone payments, minimum purchase requirements, or other performance-based obligations. It is essential for assessing the long-term financial liabilities associated with a product's lifecycle.